In 2020, Sanofi invested nearly 500 million euros ($554 million) to build what it then called its Evolutive Vaccine Facility (EVF). The idea later evolved into including the manufacture of biologics.

Sept 27 (Reuters) - The U.S. Food and Drug Administration has approved Sanofi (SASY.PA), opens new tab and Regeneron's (REGN.O), opens new tab blockbuster drug Dupixent for patients with a chronic ...

Sanofi is in the final stages of selling its European generics business, Zentiva, to private equity firm Advent International. The companies have signed a share purchase agreement valued at €1.9 ...

Sanofi said an oral treatment for multiple sclerosis, tolebrutinib, met its key goal in a Phase 3 study, potentially clearing the way for regulatory approval, although in two other studies ...

NEW YORK, Sept 23 (Reuters) - Sanofi's (SASY.PA), opens new tab chief executive, Paul Hudson, said in an interview on Monday that the company is poised for strong growth from a variety of new ...

After a series of trials and tribulations, Ventyx Biosciences has received a $27 million boost from Sanofi, money that is expected to extend the biotech’s cash runway into the second half of 2026.

Sanofi has made a late entry to the radioligand party, paying 100 million euros ($110 million) upfront for global rights to a neuroendocrine tumor treatment that is nearing a filing for approval.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Since my last article, Sanofi’s stock price has continued to rise, thanks in part to strong sales of its immunology and oncology franchises. For example, Dupixent sales were €3.03 billion for ...

Sanofi is trailing behind GSK and Pfizer when it comes to vaccines for respiratory syncytial virus (RSV), but it still thinks it can be the top player in the market with a combination of its ...

(Reuters) -Sanofi has received two separate bids from private equity firms for its consumer health unit, which could be valued at 15 billion euros ($16.74 billion) or more, Bloomberg News reported ...

By Ludwig Burger (Reuters) -Sanofi's most advanced multiple sclerosis drug candidate has missed the main goal of two late-stage trials to treat relapsing forms of the disease, but in a positive ...